We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Experimental Drug Targets Diseases Caused by Toxic RNA Nucleotide Repeats

By LabMedica International staff writers
Posted on 15 Jun 2016
Print article
Image: SCA10 – An experimental drug has been designed to correct cell defects in diseases such as spinocerebellar ataxia type 10 (Photo courtesy of DTR).
Image: SCA10 – An experimental drug has been designed to correct cell defects in diseases such as spinocerebellar ataxia type 10 (Photo courtesy of DTR).
A small molecule drug designed to interact with defective RNA was shown to displace sequestered proteins and correct defects in cells derived from patients suffering from the incurable neuromuscular disorder spinocerebellar ataxia type 10 (SCA10).

SCA10 is characterized by slowly progressive cerebellar ataxia that usually starts as poor balance and unsteady gait, followed by upper-limb ataxia, scanning dysarthria, and dysphagia. The disease is exclusively found in Latin American populations, particularly those with Amerindian admixture. Abnormal tracking eye movements are common. Recurrent seizures after the onset of gait ataxia have been reported with variable frequencies among different families. Some individuals have cognitive dysfunction, behavioral disturbances, mood disorders, mild pyramidal signs, and peripheral neuropathy.

SCA10 is one of several disorders including Huntington's disease, fragile X-associated tremor ataxia syndrome, and myotonic dystrophy type 1 and 2 that are caused by repeated nucleotide RNA sequences. In SCA10 a pentanucleotide repeat disrupts mitochondria function. Currently, there have been no convenient means for correcting this type of RNA defect.

Investigators at The Scripps Research Institute (Jupiter, FL, USA) searched for small molecules that could selectively bind RNA base pairs by probing a library of RNA-focused small molecules.

They reported in the June 1, 2016, online edition of the journal Nature Communications that they had identified small molecules with benzamidine moieties that were able to bind selectively to AU (adenine-uracil) base pairs. Armed with this knowledge, the investigators synthesized a dimeric compound (2AU-2) that targeted the pathogenic RNA - containing expanded r(AUUCU) repeats - that causes SCA10 in patient-derived cells.

Treatment of SCA10-derived cells with 2AU-2 corrected various aspects of SCA10 pathology including improvement of mitochondrial dysfunction, reduced activation of the enzyme caspase 3, and reduction of nuclear foci.

"More than 30 diseases, all of them incurable, are caused by RNA repeats," said Dr. Matthew Disney, professor of chemistry at The Scripps Research Institute. "By a thorough basic science investigation, we identified small molecules that target RNA base pairs precisely. We then leveraged this information to design the first drug candidate that binds to disease-causing defects in SCA10. Application of the drug candidate returns certain aspects of those cells to healthy levels – it is like the defect is not even there. We are in the process of developing tools that allow one to design small molecules to target any RNA structural motif in a complex cellular environment."

Related Links:
The Scripps Research Institute


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
HLX
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: The study showed the blood-based cancer screening test detects 83% of people with colorectal cancer with specificity of 90% (Photo courtesy of Guardant Health)

Blood Test Shows 83% Accuracy for Detecting Colorectal Cancer

Colorectal cancer is the second biggest cause of cancer deaths among adults in the U.S., with forecasts suggesting 53,010 people might die from it in 2024. While fewer older adults are dying from this... Read more

Hematology

view channel
Image: The Gazelle Hb Variant Test (Photo courtesy of Hemex Health)

First Affordable and Rapid Test for Beta Thalassemia Demonstrates 99% Diagnostic Accuracy

Hemoglobin disorders rank as some of the most prevalent monogenic diseases globally. Among various hemoglobin disorders, beta thalassemia, a hereditary blood disorder, affects about 1.5% of the world's... Read more

Microbiology

view channel
Image: The new platform is designed to perform blood-based diagnoses of nontuberculosis mycobacteria (Photo courtesy of 123RF)

New Blood Test Cuts Diagnosis Time for Nontuberculous Mycobacteria Infections from Months to Hours

Breathing in nontuberculous mycobacteria (NTM) is a common experience for many people. These bacteria are present in water systems, soil, and dust all over the world and usually don't cause any problems.... Read more

Industry

view channel
Image: These new assays are being developed for use on the recently introduced DxI 9000 Immunoassay Analyzer (Photo courtesy of Beckman Coulter)

Beckman Coulter and Fujirebio Expand Partnership on Neurodegenerative Disease Diagnostics

Beckman Coulter Diagnostics (Brea, CA, USA) and Fujirebio Diagnostics (Tokyo, Japan) have expanded their partnership focused on the development, manufacturing and clinical adoption of neurodegenerative... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.